Please login to the form below
SCLC
This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
AbbVie slumps on trial results for would-be blockbuster Rova-T
potential while moving swiftly ahead with additional trials in both second-line (TAHOE) and first-line SCLC (MERU). ... and remain committed to developing Rova-T for the treatment of patients with SCLC.".
Latest news
-
Biotecnol taps into Cancer Research UK network for first trial
despite treatment, particularly mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), and renal cell carcinoma.
-
AbbVie's PARP inhibitor veliparib fails to deliver
Rova-T for small cell lung cancer (SCLC) and ABT-414 for the brain cancer glioblastoma.
-
Unhappy times continue at OncoMed with more disappointing results
progression-free survival (PFS) or overall survival (OS) when added to chemotherapy in patients with small-cell lung cancer (SCLC) in the PINNACLE trial.
-
Seattle Genetics signs $2bn deal for Immunomedics' cancer drug
Seattle Genetics also gets rights to the drug in other indications, including urothelial cancer (UC), small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), which are currently at
-
Pfizer's SMO inhibitor boosts survival in blood cancer trial
in a phase I/II trial in small cell lung cancer (SCLC) patients.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
-
Deal Watch April 2016
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
-
Deal Watch November 2015
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior Account Manager / Account Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Scientific Director
-
Great salary and bebefits
Subscribe to our email news alerts
PMHub
CAN advertising
Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...
Latest intelligence
- No Voice, No Choice
- Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
Quick links
Infographics
